Tesamorelin vs AOD-9604

Side-by-side comparison of Tesamorelin, AOD-9604 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Tesamorelin Tesamorelin (GHRH Analogue) Growth Hormone AOD-9604 hGH Fragment 176-191 (Anti-Obesity Drug 9604) Weight Loss
Basics
Molecular type GHRH AnaloguehGH C-terminal Fragment
Amino acids 4416
Molecular weight 5,135.8 Da1,815.1 Da
Half-life ~30 min~30 min
Route(s) SubcutaneousSubcutaneous, Oral (research)
Mechanism & Research
Primary mechanism Tesamorelin binds and activates pituitary GHRH receptors with the full-length 44-amino-acid native GHRH sequence, producing more complete pituitary signalling than the 29-amino-acid fragments (sermorelin, CJC-1295). Its … AOD-9604 mimics the lipolytic (fat-breaking) action of the C-terminal fragment of growth hormone at the beta-3 adrenergic receptor in adipocytes. By activating beta-3 receptors, it promotes lipolysis (fat cell triglyceri…
Research status FDA Approved Research Compound
Evidence summary Tesamorelin has the most extensive human clinical trial dataset of any GHRH analogue, accumulated during its FDA approval programme. Effects on visceral adiposity, metabolic parameters, and cognitive function have been s… AOD-9604 completed Phase 2b trials for obesity (METRO study) before development was discontinued. Despite clear mechanistic rationale and positive preclinical data, the Phase 2b trial did not demonstrate statistically si…
Protocol & Dosing
Typical dose 2 mg/day300–500 mcg/day
Frequency Once dailyOnce daily
Duration 26–52 weeks (clinical)8–12 weeks
Timing Before breakfast or bedtimePre-workout or morning on empty stomach (for metabolic effects)
Safety
Common side effects
  • Arthralgia (joint pain)
  • Oedema
  • Myalgia
  • Injection site redness
  • Injection site redness
  • Mild flushing
  • Headache (transient)
Contraindications
  • Active malignancy
  • Pregnancy
  • Hypopituitarism
  • Active cancer (theoretical, given GH receptor homology)
  • Pregnancy (no data)
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides CJC-1295, Sermorelin, AOD-9604 Semaglutide, Ipamorelin, Tesamorelin
Full profile Read full Tesamorelin profile → Read full AOD-9604 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.